ExploreWatchlistsPricing
  1. JP-listed companies
  2. Nano Holdings, Inc.
  3. Financials
  4. Stockholders' equity

Nano Holdings, Inc. (4571)

Market cap
¥10.6B
P/E ratio
-10.2x
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Mar 31, 20252,740-19.92%
Mar 31, 20243,421-19.56%
Mar 31, 20234,253-23.59%
Mar 31, 20225,567-25.77%
Mar 31, 20217,500-14.47%
Mar 31, 20208,769+49.14%
Mar 31, 20195,880+26.13%
Mar 31, 20184,662-53.69%
Mar 31, 201710,067-17.00%
Mar 31, 201612,129-16.36%
Mar 31, 201514,502+6.66%
Mar 31, 201413,597

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat